Introduction
Several studies have suggested that vagal nerve stimulation (VNS) is an effective therapy for reducing seizure frequency in medication resistant epileptic patients, who are poor candidates for resection or in those in whom resection has failed. 2, 4, 5, [8] [9] [10] 12, 13, 29 In previous published series, VNS achieved a 50% greater seizure frequency reduction in 50-60% of implanted patients after 1 year of therapy. 18, 19, 25 In those studies, concomitant changes in antiepileptic drugs were allowed. 3, 4, 13, 22, 23, 37, 51 A progressive decline in seizure frequency is usually found during the first year of stimulation, and it remains uncertain if the progressive improvement seen with longer VNS exposures might be ascribable to a modification in the medical therapy, rather than to sustained VNS. 14, 16, 17, 30 To date, there is only one study performed in the adult population on unchanged medical therapy during the postoperative evaluation. 30 In this study, the patients' outcome
was assessed 1 year after surgery. It has been reported that no specific antiepileptic drugs seem to have additive antiseizure effects with VNS; however, to precisely evaluate the net impact of vagal stimulation in operated patients, it is essential to maintain stable doses of the administered drugs. The purpose of this study was to prospectively evaluate the long-term effects of VNS, at 18 months of follow-up, on epileptic patients who have been on unchanged antiepileptic medication.
Materials and methods
Forty-three adult patients with medication-resistant epilepsy were treated with VNS in our institution, from 2005 to 2009. Preoperatively, all patients had undergone a complete preoperative epilepsy evaluation protocol, 39, 47 which includes videoelec-Purpose: Several studies suggest that vagal nerve stimulation (VNS) is an effective treatment for medication-resistant epileptic patients, although patients' medication was usually modified during the assessment period. The purpose of this prospective study was to evaluate the long-term effects of VNS, at 18 months of follow-up, on epileptic patients who have been on unchanged antiepileptic medication. Methods: Forty-three patients underwent a complete epilepsy preoperative evaluation protocol, and were selected for VNS implantation. After surgery, patients were evaluated on a monthly basis, increasing stimulation 0.25 mA at each visit, up to 2.5 mA. Medication was unchanged for at least 18 months since the stimulation was started. Patients were evaluated on a monthly basis, increasing stimulation by 0.25 mA at each visit up to 2.5 mA, if there were no major adverse effects (except for one case, in whom the stimulation was set at 2.75 mA). When patients reached this level of stimulation, they were reviewed every 6 months, except for those that needed more frequent follow-ups due to medical reasons. In the postoperative visits, seizure frequency, side effects, and other significant information reported by family members and caregivers, was collected. Seizures were classified, according to their frequency, as daily seizures if the patient had 7 or more per week, as weekly seizures if the patient had from 1 to 6 a week, and as monthly seizures if the patient had less than four per month. Responders were defined as having a 50% or greater reduction in seizure frequency with respect to the mean seizure frequency during the last year before the implantation of VNS. Changes in the pharmacological treatment were not allowed during the first 18 months of postoperative follow-up.
Group mean differences in percentage of reductions in seizure frequency were tested non-parametrically if variables were not distributed normally, and using the paired Student's t-test for normal distributions. Normality was evaluated using the Kolmogorov-Smirnov test. The software SPSS 17.0 was used for statistical analysis. The significance level was set at p = 0.05. Results are shown as the mean AE SEM, except where otherwise indicated. This study was approved by the local ethics committee board.
Results
Clinical characteristics of the patients are shown in Table 1 . The study involved 22 women and 21 men. The mean age at epilepsy onset was 9 (AE9.9) years, and the mean age at implantation was 34 (AE11.8) years. The majority of patients had daily multifocal or generalised seizures (51%), and 12 patients had undergone a previous surgery for epilepsy, which proved unsuccessful.
The mean seizure frequency reduction at 18 months follow-up was 46.6% (AE35.5) ( Table 2 ). Twenty-seven of the 43 patients included in the analysis (63%) were responders. Among the 27 responders, seven patients (16% of the total sample), had a greater than 90% seizure frequency reduction. Four of these 7 patients with !90% of seizure reduction had frontal seizures (one of them was seizure-free), one patient had occipital-temporal seizures, and 2 patients had generalised seizures. Clinical features of responders and non-responders are summarised in Table 2 .
Patients and caregivers reported other positive aspects derived from VNS: Ten patients referred to a reduction in seizure duration and severity; three patients reported a disappearance of the generalised tonic-clonic seizures, with persistence of the other seizure types; ten patients with mental retardation showed an improvement in alertness; and one patient experienced a nonquantified weight loss. One patient, however, reported an increase in the duration and intensity of his seizures.
Twenty-two patients experienced side-effects. The most common were mild, consisting in hoarseness, neck tingling or occasional coughing at the time when the signal was on, all of which were usually well tolerated. Two patients had intermittent dyspnoea, and another patient experienced occasional episodes of dysphagia with stimulation. Irritability was reported by two families, in the context of a general improvement in the level of alertness. Five had severe side effects, requiring their VNS generators to be inactivated or explanted. Three of the 5 patients that stopped receiving stimulation had been responders. Reasons for explantation were infection in two patients, and odynophagia, in one patient. One patient had an exacerbation of a previous behaviour disturbance, with severe aggressiveness, which improved when the stimulator was inactivated. Seizure reduction was maintained after the stimulation was stopped. Another stimulator was removed at family request, owing to a persistent abdominal pain.
For the 38 patients that continued receiving stimulation, intensity fluctuated between 0.5 mA and 2.75 mA. Mean seizure frequency reduction by stimulation intensity is represented in Fig. 1 . Two patients receiving stimulation at 0.25 mA, obtained a greater than 90% reduction in the frequency of their seizures. The responder rate for patients at !2 mA was 71% (17 out of 24 patients, whereas it was 53% for those at <2 mA (7 out of 19 patients).
The relationship between the clinical outcome and the intensity of stimulation, epilepsy type and location, and frequency did not reach statistical significance. Patients with generalised epilepsy had a mean seizure frequency reduction of 49.4 AE 34.8%, and those with focal epilepsy, 44.5 AE 35.6%. Among them, patients with temporal epilepsy had a seizure reduction rate of 63.0 AE 34.8% (Fig. 2) . We analysed the percentage of responders by epilepsy location, and we found that 4 out of 5 (80%) of the patients with temporal lobe epilepsy, 15 out of 22 (74%) of the patients with generalised epilepsy, 6 out of 13 (46%) of the patients with frontal epilepsy, and 1 out of 3 (33%) of those with other extratemporal seizures, were responders.
Twenty-three out of 34 (67%) patients with daily seizures responded to stimulation, whereas those with monthly or 5 weekly seizures had a responder rate of 50% (2 out of 5, and 2 out of 4 patients, respectively). Eight out of 12 (66%) patients with a history of previous epilepsy surgery were responders, while of those without a previous operation, 10 out of 21 (50%) responded to stimulation.
Discussion
Given the complexity and degree of disability of patients treated with VNS, most of the studies have allowed modification of the patients' antiepileptic medication types and doses after the implantation 32, 33 ; this may significantly affect the analysis of the results. 36, 41, [44] [45] [46] 48, 49 To our knowledge, this is the only long-term prospective study that has been performed on VNS for adults with no changes in the medical treatment during the follow-up (6). In our series, the percentage of epileptic patients that achieved a 50% or greater seizure frequency reduction, 18 months after VNS implantation, was 63%, and the mean reduction in seizure frequency was 46.6%. In various published series, an equal or higher than 50% reduction in seizure frequency was achieved in about 50% of patients (18.4-67%) , and the mean reduction in the frequency of seizures was 42.8% (range 28-66%). 7, 15, 21, 35, 43, 53 In the only study to date, performed on an adult population where medication type and doses were held totally constant during the postoperative period, the median reduction in seizure frequency, 1 year after the stimulation was started, was 63%. 30 The implantation of VNS implies frequent visits to clinic and therefore the possibility of a more careful adjustment of medical therapy; moreover, patients might derive an improvement in seizure frequency from the administration of new drugs. On the other hand, our results are similar to those obtained in institutions with extensive experience in epilepsy and vagal stimulation, suggesting that changes in medication therapy during the period of adjustment of parameters do not appear to benefit patients. 30 The absence of medication changes, which can interfere with the evaluation of seizure frequency and side effects, may be helpful in optimising stimulation settings and thus, in improving response rates. Moreover, as most neurologists and patients hope to decrease the number of medications after VNS placement, it is possible that a reduction in the medication regime might have had a detrimental effect on patients undergoing VNS.
There are several studies suggesting that high intensity of stimulation corresponds to better outcome, although some other authors consider the time of exposure to the treatment, and not the intensity of stimulation, the key factor that leads to appropriate responses. 15, 18, 26, 30, 40 In our series, the relationship between the clinical outcome and the intensity of stimulation was independently analysed for the duration of stimulation, since the outcome was uniformly considered at 18 months. Outcome differences according to intensity of stimulation were not statistically significant, and there were also some very satisfactory results besides the usual therapeutic values of stimulation. 31, 34 Other than frontal focal epilepsy and younger age at the VNS implantation, have also been considered positive predictive factors for VNS response in various studies, 26, 30 although no definite conclusions have been drawn. 23, [26] [27] [28] In our series, 15 out of 22 patients with generalised epilepsy were responders, and 4 of the 7 patients that obtained a frequency reduction of more than 90% had frontal epilepsy. It is also of note that our patients' mean epilepsy duration at the time of surgery (25 years), was very high. 30, 42 Finally, the existence of a previous surgery has been suggested as a negative predictive factor after VNS. 4 It is of importance to confirm these results, because they might substantially modify VNS patient selection. In our series, 8 out of 12 patients with a previous surgery attained satisfactory results from stimulation. Further studies on VNS for epileptic patients on unchanged medication are needed to elucidate which are the main predictive factors of responsiveness to VNS. The impact of the VNS in other domains of interest has been documented in several studies. 20, 42, 43 The improvement in mood and cognitive performance has led to indicate VNS for patients with chronic depression, although later results have been conflicting. 42, 43 In our series, a positive effect on alertness has been observed in almost a quarter of the patients. Reduction in seizure frequency and independent mechanisms for regulation of various centroencephalic nuclei have been implicated in these processes, although they have not been yet elucidated. 23, 42, 43, 50 It must be said that, occasionally, the improvement of the level of alertness has not been linked to an improvement in the quality of life, since patients are more aware of the limitations of their illness. In our series, previous behaviour disorders were exacerbated. 1, 6, 22, 23, 52, 54 There are limitations to our study, since a control group was not included in the analysis. It is difficult to compare previously reported series of patients with drug-resistant epilepsy under the best medical treatment with our series because of differences in the definition of drug-resistant epilepsy and patient characteristics. 11, [55] [56] [57] [58] In previous reports, the remission rate for epileptic patients that have been resistant to at least two antiepileptic drugs oscillates between 4 and 5% per year, and around 50% of patients might be responders in the long term. 11, 24, 38, 54, 55 VNS, as any chronic implanted medical device, requires unambiguous positive evidence for therapeutic superiority over conservative treatment in regards to costs, risks, and adverse effects. Despite the fact that our study eliminates the confounding factor of medication changes during the assessment period after VNS implantation, there is a need for long-term controlled prospective studies with patients under VNS, and without changes in medication, to confirm our results.
Conclusions
62.8% of our series of 43 medication-resistant epileptic patients experienced a significant long-term seizure reduction after VNS, even in a situation of unchanged medical therapy. Patient characteristics predictive of VNS responsiveness remain subject to investigation. It is necessary to perform controlled studies with a larger number of subjects on unchanged antiepileptic medication to draw definitive conclusions
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